UBS Reiterates Buy on Medtronic (MDT) Following 1Q Report

August 26, 2016 8:55 AM EDT
Get Alerts MDT Hot Sheet
Price: $83.91 -0.13%

Rating Summary:
    20 Buy, 16 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MDT Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

UBS reiterated a Buy rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $96.00 (from $92.00), following the company's 1Q earnings report. Management reiterated F17 guidance of 5-6% top-line adjusted CC growth and EPS guidance of $4.60-4.70.

Analyst Matt Miksic commented, "Management delivered on its F1Q17 guidance of 5.0 – 5.5% adjusted revenue growth (excluding impact of the extra week last year) and its 'down slightly' EPS guidance by 2c (including +2c from tax and -1c from other non-op expenses). There was a 70 bps contribution from acquisitions in the quarter, as expected, and in-line with the 50-100 bps of growth from M&A annually, as laid out in management's long-term plan at the recent investor day. We view the sustainable top line performance as impressive, and continued double-digit CC EPS growth as attractive, particularly given the expanded size of the company (now ~$120 bil market cap). So with more appropriate guidance set on sales growth and EPS, we expect investors to be more focused on these metrics, and we see F17 as less of a hand-wringer than F16 on a quarter-to-quarter basis. We reiterate our Buy rating on top pick MDT, upping our target from $92 to $96. We view weakness post-F1Q results as an attractive buying opportunity."

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $85.39 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS, Earnings

Add Your Comment